OPK Opko's next-generation prostate cancer test should reduce unnecessary biopsies by 50%

Opko just launched its new prostate cancer diagnostic test (called the 4KScore ) in Europe and should begin selling in the United States later this year. This test is being launched in the U.S. as a Laboratory Developed Test ("LDT") under FDA guidelines, and no additional FDA approvals are necessary. Once investors realize that Opko will be generating a new revenue stream in a multibillion-dollar market, we could see major share price appreciation.